Welcome to our dedicated page for Guardian Pharmacy Services news (Ticker: GRDN), a resource for investors and traders seeking the latest updates and insights on Guardian Pharmacy Services stock.
Guardian Pharmacy Services, Inc. provides long-term care pharmacy services for residents of long-term health care facilities. The company partners with LTCFs through a locally based pharmacy model to dispense medications and deliver technology-enabled clinical and administration services intended to support drug-regimen adherence and reduce medication-administration errors.
Recurring GRDN news covers quarterly results and guidance, resident and prescription-volume trends, the effects of drug-pricing changes, healthcare conference presentations, and capital-structure activity involving Class A common stock. Company updates also reference its pharmacy network, facility relationships, and service categories across assisted living, behavioral health, group home, and other long-term care settings.
Guardian Pharmacy Services (NYSE: GRDN) launched a proposed underwritten public offering of 5,000,000 Class A shares on March 18, 2026, including 3,980,000 shares by selling stockholders and 1,020,000 newly issued shares by Guardian.
The underwriters have a 30-day option for up to an additional 750,000 shares. Guardian intends a non-dilutive "Synthetic Secondary": net proceeds it receives will be used to repurchase an equal number of Class A shares, keeping total outstanding Class A shares unchanged. A shelf registration on Form S-3 became effective November 3, 2025.
Guardian Pharmacy Services (NYSE: GRDN) reported Q4 2025 revenue of $397.6M (+17% YoY; organic +12%) and Q4 Adjusted EBITDA of $39.5M (+53% YoY). Full-year 2025 revenue was $1.45B (+18%); Adjusted EBITDA $115.1M (+27%); net income $49.0M versus a ($71.0M) loss in 2024. Cash totaled $65.6M at year-end. The company raised 2026 Adjusted EBITDA guidance to $120M–$124M while maintaining the prior 2026 revenue outlook of $1.40B–$1.42B. Operational highlights included one acquisition, improved vaccine profitability, and ~205,000 residents served at year-end.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference.
CEO Fred Burke and CFO David Morris will take part in a fireside chat on Monday, March 16, 2026 at 10:40 a.m. ET. A live audio webcast and a replay available for 90 days will be hosted on the company investor site.
Guardian Pharmacy Services (NYSE: GRDN) will present at the Raymond James Institutional Investors Conference in Orlando on Monday, March 2, 2026 at 1:40 p.m. ET. A live audio webcast will be available via the company's investor site, with a replay accessible shortly after the event for 90 days.
Guardian Pharmacy Services (NYSE: GRDN) will release fourth quarter and full‑year 2025 financial results after market close on Wednesday, March 11, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss results.
The call is available via audio webcast at the company's investor site and by dialing the provided U.S. and international numbers; a replay will be available shortly after the call and remain online for approximately 60 days.
Guardian Pharmacy Services (NYSE: GRDN) reiterated its 2025 guidance and issued initial 2026 outlook ahead of its J.P. Morgan Healthcare Conference presentation on January 14, 2026. The company reaffirmed 2025 revenue guidance of $1.43B–$1.45B and adjusted EBITDA of $104M–$106M. For 2026 Guardian expects revenue of $1.40B–$1.42B after Inflation Reduction Act drug price reductions and WAC cuts, and adjusted EBITDA of $115M–$118M (~11% growth vs. 2025 guidance) with adjusted EBITDA margin above 8%. The company also completed a single-location pharmacy acquisition in Montana to add a new territory.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026. The company’s leadership will host investor meetings that day and deliver a presentation at 4:30 p.m. PT. A live audio webcast will be available at https://investors.guardianpharmacy.com, with a replay posted shortly after the presentation and available for 30 days.
Guardian Pharmacy Services (NYSE: GRDN) reported third quarter 2025 results and raised full-year guidance. Q3 revenue was $377.4M (+20% YoY) and Adjusted EBITDA was $27.3M (vs. $23.0M). Net income was $9.6M vs. a $(105.8)M loss year-ago. Residents served were ~204,000 (+13% YoY). Diluted EPS was $0.15 with Adjusted EPS of $0.25. Cash totaled $36.5M and there was no long-term debt outstanding under the credit facility.
Guardian raised FY2025 guidance to $1.43B–$1.45B revenue and $104M–$106M Adjusted EBITDA (excludes future acquisitions). Operationally, Guardian closed an acquisition in Oregon to enter the Pacific Northwest. A Form S-3 shelf was filed allowing potential issuance/resale of Class A shares.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Stephens Investment Conference in Nashville, TN on Wednesday, November 19, 2025. The company will host investor meetings and Fred Burke, co-founder and CEO, will appear in a fireside chat at 11:00 a.m. CT (12:00 p.m. ET). A live audio webcast will be available at the company investor site and a replay will be accessible shortly after the event for 90 days.
Guardian Pharmacy Services (NYSE: GRDN) filed a Form S-3 shelf registration on October 14, 2025 to permit the issuance of up to 1,020,000 new Class A shares and the potential resale of up to 4,980,000 outstanding Class A shares by selling stockholders.
Guardian said neither it nor the selling stockholders have immediate plans to sell under the shelf. The filing is not yet effective. Guardian also executed lock-up agreements covering approximately 17,188,059 shares and the automatic conversion of 12,759,054 Class B shares on March 28, 2026, restricting sales through June 30, 2026. As of September 30, 2025, there were 36,253,744 Class A shares outstanding.